Welcome to our dedicated page for Nuwellis news (Ticker: NUWE), a resource for investors and traders seeking the latest updates and insights on Nuwellis stock.
Nuwellis, Inc. (Nasdaq: NUWE) is a medical technology and medical device company centered on precision fluid management for patients with cardio-renal conditions and fluid overload. News about Nuwellis frequently highlights clinical data, regulatory milestones, pediatric innovation, and business updates related to its Aquadex SmartFlow® ultrafiltration system and its Vivian™ pediatric continuous renal replacement therapy (CRRT) platform in development.
Readers of this NUWE news page can follow company announcements on topics such as new patents for extracorporeal safety technologies, NIH grant-supported development of the Vivian pediatric system, and multi-center registries like ULTRA-Peds that examine real-world Aquadex use in critically ill children. Nuwellis also issues news about clinical experiences at hospitals, including studies presented at nephrology conferences that explore Aquadex applications in acute kidney injury, post-cardiac-surgery fluid overload, and complex critical-care cases.
In addition to clinical and technology updates, Nuwellis regularly reports quarterly financial results, at-the-market equity offering arrangements, and other material events through press releases and SEC-referenced communications. These updates provide insight into revenue trends, product launches such as new catheter sizes or circuits, and strategic steps like focusing on U.S. market growth.
Investors, clinicians, and researchers can use this news feed to track how Nuwellis is advancing its Aquadex platform, expanding into pediatric and hospital-based outpatient settings, and progressing the Vivian pediatric CRRT system. Returning to this page allows users to monitor ongoing developments in the company’s cardio-renal strategy, intellectual property portfolio, and regulatory and clinical milestones associated with NUWE.
Nuwellis (Nasdaq: NUWE) appointed David A. McDonald and Martin J. Emerson to its Board of Directors, effective February 24, 2026. The hires add public company leadership, medical device commercialization experience and capital-markets expertise to support execution of the company’s strategic priorities.
Martin Emerson brings experience leading device companies through scaling and exits, including an acquisition by BTG, and prior leadership at an organization with over $500 million in annual revenue. David McDonald returns to the board with 25+ years in healthcare capital markets and a track record of raising nearly $200 million.
Nuwellis (Nasdaq: NUWE) will report Q4 and full-year 2025 financial results on March 10, 2026. A conference call and webcast are scheduled for 9:00 AM ET to discuss results and provide a business update.
According to Nuwellis, the live webcast and an audio archive will be available on the company Investors page, and dial-in details and conference ID NUWEQ4 are provided for listeners.
Nuwellis (Nasdaq: NUWE) announced the appointment of Carisa Schultz as Chief Financial Officer, effective February 2, 2026. Ms. Schultz joins from NeueHealth, where she served as Vice President of Finance and led enterprise finance, treasury, and corporate development.
Her background includes roles at Boston Scientific and Big Four public accounting, bringing public-company healthcare and medical-technology finance experience to support Nuwellis’ next phase of growth.
Nuwellis (Nasdaq: NUWE) announced a priced-at-the-market private placement and warrant inducement expected to raise approximately $5.0 million in gross proceeds prior to fees. The transaction includes 994,537 shares (or pre-funded warrants) plus 1,989,074 private placement warrants at a combined price of $3.09.
The company agreed to a warrant inducement: certain existing warrants will be exercised to buy 623,585 shares at an amended exercise price of $3.09, and Nuwellis will issue 1,247,170 new warrants exercisable at $2.84 for five years after resale registration effectiveness. Closing is expected on or about January 30, 2026. Ladenburg Thalmann served as placement agent.
Nuwellis (Nasdaq: NUWE) entered a Securities Purchase Agreement to acquire Rendiatech Ltd. on Jan 29, 2026, expanding its cardiorenal portfolio into real-time kidney function monitoring. The move adds Rendiatech’s Clarity™ automated continuous urine-output monitoring to Nuwellis’ critical-care offerings and remains subject to customary closing conditions.
The company expects to leverage existing commercial infrastructure and clinical relationships to integrate the technology and pursue future urine-based analytics and broader kidney assessment capabilities.
Nuwellis (Nasdaq: NUWE) announced board changes effective January 21, 2026: Katharyn Field and Mika Grasso were appointed to the board, and Dave McDonald, Mike McCormick, and Dr. Maria Costanzo resigned.
The company said the resignations were not due to any disagreement with Nuwellis on operations, policies, or practices. Management thanked the departing directors and said the new directors bring financial, operational, and governance experience. Additional details are disclosed in the company’s SEC Form 8-K.
Nuwellis (Nasdaq: NUWE) announced that the U.S. Patent and Trademark Office issued a new U.S. patent tied to U.S. Patent Application No. 18/298,810 on January 6, 2026.
The patent covers advanced safety mechanisms for blood return line clamps in extracorporeal blood filtration systems, with specific relevance to pediatric extracorporeal therapy and the Vivian™ Pediatric CRRT System currently in development. Nuwellis said the invention aims to improve reliability and consistency of blood flow control, support stable system performance for small patient volumes, and strengthen the company’s pediatric intellectual property portfolio and cardio-renal strategy.
Nuwellis (Nasdaq: NUWE) announced real-world data from Lenox Hill Hospital presented at ASN Kidney Week 2025 showing Aquadex ultrafiltration used across critical-care indications including oliguric AKI, post-cardiac-surgery volume overload, and pre-operative ESRD optimization.
The retrospective review of 69 cases (2018–2024) reported an average 6.4 liters removed per patient over a mean 78 hours with stable hemodynamics, including patients on vasopressors, supporting broader clinical utility of precision ultrafiltration.
Nuwellis (Nasdaq: NUWE) announced that a leading children’s hospital in the Northeast U.S. has initiated an Aquadex Ultrafiltration Program on Dec. 4, 2025. Pediatric nephrology and cardiology teams are adopting Aquadex for its minimal extracorporeal volume and real-time hematocrit monitoring to manage fluid-sensitive, high-acuity pediatric patients.
The company says Aquadex usage is expanding across leading children’s hospitals nationwide and is being integrated into care pathways for complex cardiac, cardio-renal, and critical care cases, supporting Nuwellis’ pediatric growth strategy.
Nuwellis (Nasdaq: NUWE) reported third quarter 2025 results on Nov 12, 2025, delivering $2.2 million total revenue, down 6% year‑over‑year and up 29% sequentially.
The company reported a 65.2% gross margin, operating expenses of $4.1 million (up 30% YoY) and an operating loss of $2.7 million. Nuwellis ended the quarter with $3.1 million cash, no debt, and raised $1.9 million through an ATM.
Operational milestones include first Aquadex therapies delivered in hospital‑based outpatient settings under a new CMS code, U.S. launch of a 24‑hour circuit and dual‑lumen extended‑length catheter, accelerated pediatric development via an NIH‑funded collaboration and a newly issued U.S. patent, plus a manufacturing transition and international wind‑down to focus on U.S. growth.